Agilon Health announced that Tim O’Rourke will become its chief executive officer, effective May 7, 2026. Ronald A. Williams will remain as chairman of the board, ensuring continuity as the company moves into a new phase of its turnaround plan.
Agilon’s 2025 results were a net loss of $391 million and a negative medical margin of $57 million, reflecting elevated medical cost trends, prior‑period development expenses, and a decline in risk‑adjustment revenue. For 2026, the company has guided a medical margin of $300 million to $350 million and revenue of $5.41 billion to $5.58 billion, with adjusted EBITDA near breakeven at a loss of $15 million to a profit of $15 million.
The turnaround strategy is built on four pillars: improved executional rigor, stronger payor relationships, enhanced clinical performance, and disciplined cost management. Agilon has also exited underperforming markets and contracts, reduced Part D exposure, and optimized its cost structure. O’Rourke’s background in value‑based care on both the payor and provider sides positions him to accelerate these initiatives and drive sustainable growth.
Ronald A. Williams said, “Tim is the right leader to take agilon forward. He has operated on both sides of the healthcare equation, from inside the world of distributed care delivery and across a leading Medicare Advantage payor, and brings a deep understanding of what is needed to succeed in value‑based care.” He added, “While we were not satisfied by our 2025 financial performance, the transformation initiatives are delivering tangible benefits which support our expectation for material improvement in 2026. Based on the progress we have made and the momentum we are carrying into 2026, I am confident in our trajectory and firmly believe agilon and our partners are entering the next phase with a stronger foundation, a more resilient model, and a clear path to sustainable value creation.”
Investors have responded positively to Agilon’s 2026 guidance, which signals a return to profitability and a clear path to breakeven. The company’s focus on operational discipline, cost reductions, and value‑based care partnerships underpins the confidence expressed by management and the market’s favorable reception of the new CEO appointment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.